Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases

Autor:	Nicola Cresti, K Donaldson, Ruth Plummer, James Spicer, Linda Hogarth, Keiko Kawaguchi, Debashis Sarker, Javier Garcia-Corbacho, J Posner, Sanjeev Deva, Duncan I. Jodrell, A Arimura, Eugene P. Frenkel, Richard D. Baird
Rok vydání:	2015
Předmět:	Cancer Research Oncology ErbB medicine.drug_class business.industry Phase (matter) Cancer research medicine skin and connective tissue diseases business neoplasms Tyrosine-kinase inhibitor
Zdroj:	Journal of Clinical Oncology. 33:2511-2511
ISSN:	1527-7755 0732-183X
Popis:	2511 Background: S-222611 is an oral, reversible ErbB tyrosine kinase inhibitor of EGFR and HER2 with potent pre-clinical activity. MTD was not reached during dose-escalation, even at the maximum d...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b2b9b63911142741ea8a9bcdadeb62cf https://doi.org/10.1200/jco.2015.33.15_suppl.2511 Zobrazit plný text záznamu